Eric Larson
Eric R. Larson is a mechanical engineer with over 30 years' experience in plastics. He has helped develop products ranging from boogie boards, water basketball games and SCUBA diving equipment to disposable lighters, cell phones and handheld medical devices. Eric is owner of Art of Mass Production (AMP), an engineering consulting company based in San Diego, CA. AMP provides services to manufacturing companies in the consumer electronics, wireless, and medical device industries. Eric is also moderator of the blog site plasticsguy.com, where he writes about plastics technology and its effect on people and the planet.
ARTICLES BY ERIC LARSON
Medtech Material Selection For Performance And Feel
When designing a medical device, material selection can be difficult, especially with thousands of plastic material options available. While material properties, environmental effects, regulatory requirements, and cost almost always are considered, "feel" is often overlooked – despite its importance to user and patient satisfaction, as well as market success.
Continue Reading..
Medical Plastics: Material Selection Based On Feel
From prioritizing material properties to establishing desired values for each property, selecting plastic materials based on feel is a complicated undertaking. To elicit the most desirable user response from the device, it can be helpful to consider the what, rather than the how.
Continue Reading..
Mass Consolidation Sweeps Through Medtech Industry: What Startups Can Do About It
Mass consolidation is sweeping up small medtech organizations. Med device startups and early-stage companies that want to be part of this rebirth must develop strategies for taking advantage of the new ecosystem.
Continue Reading..
06.28.26 -- Rethinking CQV In A Digital, Agile Manufacturing Landscape
06/28/26 Med Device Online Newsletter
Continue Reading..
06.23.26 -- CQV In The Digital Age: Adapting Validation For Agile Manufacturing
06/23/26 Med Device Online Newsletter
Continue Reading..
Does The FDA's Plausible Mechanism Pathway Revolutionize The Way All Risks Are Analyzed?
The FDA's new guidance on plausible mechanisms represents the first regulatory guidance-driven example of where the primary information source of a risk analysis is shifted from data-based to mechanism-based evidence.
Continue Reading..
Tissues And Complex Materials Why Toxicology-Chemistry Collaboration Matters
Gain practical insights into overcoming the challenges of complex material characterization through effective collaboration between chemistry and toxicology to support robust regulatory and risk assessment strategies.
Continue Reading..
Hormuz Deal Brings Cautious Relief To Pharma Packaging Supply Chains
Restrictions and fear on the Hormuz Strait have fractured supply chains, especially for primary materials used in pharmaceutical packaging.
Continue Reading..
06.18.26 -- Inside FDA's First 100 QMSR Inspections
06/18/26 Med Device Online Newsletter
Continue Reading..